• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Castle Biosciences (CSTL) Expands On New Clinical Data, Is It Still 19% Below Fair Value?

    Simply Wall St·10/01/2026 21:13:18
    Listen to the news

    Castle Biosciences stock reacts to new clinical data and expansion moves

    Castle Biosciences (CSTL) drew investor attention after publishing fresh clinical data on its AdvanceAD-Tx atopic dermatitis test, opening a new Scottsdale lab facility and flagging upcoming DecisionDx-Melanoma data at the 2026 EADV Congress.

    Recent clinical milestones and the new Scottsdale facility have coincided with a sharp 47.37% 90 day share price return, while the year to date share price performance is down 7.81%. Over the longer run, total shareholder return of 59.83% over one year and 139.10% over three years points to investors reassessing Castle Biosciences as these data sets and capacity investments influence expectations around its tests and perceived risk profile.

    Scan how other molecular diagnostics and healthcare test providers are priced by tracking the list of solid balance sheet and fundamentals (25 results) alongside Castle Biosciences after this latest run of clinical and expansion news.

    Castle Biosciences now has fresh data, a larger lab footprint and a share price that has surged 47% over 90 days. The bigger question is whether that business strength is already fully reflected in US$35.53.

    Most Popular Narrative: 19% Undervalued

    Against the last close at $35.53, the most followed valuation story around Castle Biosciences points to a fair value of $44.00. This puts the recent clinical momentum and analyst expectations under a brighter spotlight.

    Castle's rapid expansion of its test menu, especially into high-growth, underpenetrated indications like gastrointestinal diagnostics (TissueCypher) and new pipeline areas such as atopic dermatitis, positions the company to tap into substantially larger patient populations and diversify revenue streams, directly supporting long-term revenue growth.

    The ongoing shift toward precision and individualized medicine across healthcare systems, combined with Castle's robust real-world evidence (e.g., NCI SEER study showing 32% reduction in melanoma mortality), sets the stage for broader clinical adoption and increased commercial and payer demand, likely boosting test volumes and supporting higher revenues.

    See why 4 investors see Castle Biosciences as 19% undervalued.

    Result: Fair Value of $44.00 (UNDERVALUED)

    Still, the Castle Biosciences story can change quickly if payer decisions on tests like DecisionDx-SCC remain unfavorable or if rising commercial costs outpace test adoption.

    Find out about the key risks to this Castle Biosciences narrative.

    Next Steps

    If this mix of enthusiasm and caution around Castle Biosciences leaves you on the fence, consider taking action while the data and sentiment are fresh and weigh the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Castle Biosciences?

    Do not stop your research at Castle Biosciences. Broaden your watchlist with focused stock ideas that match your risk tolerance and income goals using targeted screeners.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.